173 related articles for article (PubMed ID: 24074836)
1. CD31 expression in plasmacytic/plasmablastic lesions.
Plocharczyk E; Wakely PE
Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features of B-Cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases.
Oliveira JL; Grogg KL; Macon WR; Dogan A; Feldman AL
Am J Surg Pathol; 2012 Sep; 36(9):1364-70. PubMed ID: 22895269
[TBL] [Abstract][Full Text] [Related]
3. The ultrastructural features of plasmablastic lymphoma.
Goedhals J; Beukes CA; Cooper S
Ultrastruct Pathol; 2006; 30(6):427-33. PubMed ID: 17182435
[TBL] [Abstract][Full Text] [Related]
4. High-grade plasmablastic neoplasm of humerus in an HIV-negative patient, which was indeterminate between plasmablastic lymphoma and plasmablastic myeloma.
Mondal SK; Bera H; Biswas PK; Mallick MG
J Cancer Res Ther; 2011; 7(2):214-6. PubMed ID: 21768719
[TBL] [Abstract][Full Text] [Related]
5. Peroxiredoxin I is differentially expressed in multiple myelomas and in plasmablastic lymphomas.
Demasi AP; Magalhães MH; Furuse C; Araújo NS; Junqueira JL; Araújo VC
Oral Dis; 2008 Nov; 14(8):741-6. PubMed ID: 18565146
[TBL] [Abstract][Full Text] [Related]
6. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.
Vega F; Chang CC; Medeiros LJ; Udden MM; Cho-Vega JH; Lau CC; Finch CJ; Vilchez RA; McGregor D; Jorgensen JL
Mod Pathol; 2005 Jun; 18(6):806-15. PubMed ID: 15578069
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.
Colomo L; Loong F; Rives S; Pittaluga S; Martínez A; López-Guillermo A; Ojanguren J; Romagosa V; Jaffe ES; Campo E
Am J Surg Pathol; 2004 Jun; 28(6):736-47. PubMed ID: 15166665
[TBL] [Abstract][Full Text] [Related]
8. Unusual case of plasmablastic non-Hodgkin's lymphoma located in the liver. First case reported in an AIDS patient.
Metta H; Corti M; Maranzana A; Schtirbu R; Narbaitz M; De Dios Soler M
Ann Hepatol; 2009; 8(3):242-5. PubMed ID: 19841505
[TBL] [Abstract][Full Text] [Related]
9. Diffuse large B-cell lymphomas with plasmablastic differentiation.
Teruya-Feldstein J
Curr Oncol Rep; 2005 Sep; 7(5):357-63. PubMed ID: 16091196
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease.
Varricchio S; Pagliuca F; Travaglino A; Gallo L; Villa MR; Mascolo M
J Cutan Pathol; 2019 Aug; 46(8):619-622. PubMed ID: 31025408
[TBL] [Abstract][Full Text] [Related]
11. FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis.
Cho U; Cha HJ; Kim HJ; Min SK; Kim HK; Jung HR; Park G; Kim JE
Clin Exp Med; 2024 Jan; 24(1):18. PubMed ID: 38280044
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells.
Qi CF; Zhou JX; Lee CH; Naghashfar Z; Xiang S; Kovalchuk AL; Fredrickson TN; Hartley JW; Roopenian DC; Davidson WF; Janz S; Morse HC
Cancer Res; 2007 Mar; 67(6):2439-47. PubMed ID: 17363561
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
Balagué O; Martínez A; Colomo L; Roselló E; Garcia A; Martínez-Bernal M; Palacín A; Fu K; Weisenburger D; Colomer D; Burke JS; Warnke RA; Campo E
Am J Surg Pathol; 2007 Sep; 31(9):1310-22. PubMed ID: 17721185
[TBL] [Abstract][Full Text] [Related]
14. Plasmablastic lymphomas with light chain restriction - plasmablastic extramedullary plasmacytomas?
Boy SC; van Heerden MB; Raubenheimer EJ; van Heerden WF
J Oral Pathol Med; 2010 May; 39(5):435-9. PubMed ID: 20537055
[TBL] [Abstract][Full Text] [Related]
15. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Guedez L; Martinez A; Zhao S; Vivero A; Pittaluga S; Stetler-Stevenson M; Raffeld M; Stetler-Stevenson WG
Blood; 2005 Feb; 105(4):1660-8. PubMed ID: 15479729
[TBL] [Abstract][Full Text] [Related]
16. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
17. Human myeloma cells express the CD38 ligand CD31.
Vallario A; Chilosi M; Adami F; Montagna L; Deaglio S; Malavasi F; Caligaris-Cappio F
Br J Haematol; 1999 May; 105(2):441-4. PubMed ID: 10233418
[TBL] [Abstract][Full Text] [Related]
18. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study.
Schwartz TH; Rhiew R; Isaacson SR; Orazi A; Bruce JN
Neurosurgery; 2001 Nov; 49(5):1039-44; discussion 1044-5. PubMed ID: 11846895
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of plasma cell morphology in multiple myeloma.
Paule B; Quillard J; Bisson M; Kahn MF; Massias P
Nouv Rev Fr Hematol (1978); 1988; 30(4):209-12. PubMed ID: 3194186
[TBL] [Abstract][Full Text] [Related]
20. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
Morley AM; Verity DH; Meligonis G; Rose GE
Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
